One vs Five Days of Octreotide Infusion for Acute Esophageal Variceal Bleeding: A Randomized Controlled Trial
Authors:
- Sakkarin ChirapongsathornSCSakkarin Chirapongsathorn
- Arunchai ChangACArunchai Chang
- Dhanusorn WanichagoolDWDhanusorn Wanichagool
- Witsarut ManasirisukWMWitsarut Manasirisuk
- Uayporn KaosombatwattanaUKUayporn Kaosombatwattana
- Attapon RattanasuparARAttapon Rattanasupar
- Nuttida PolpanichNPNuttida Polpanich
- Anuchit SuksamaiASAnuchit Suksamai
- Kanit BunnagKBKanit Bunnag
- 15 October 2025
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (8) , 1885-1894
Abstract
INTRODUCTION: The optimal duration of octreotide infusion for esophageal variceal bleeding remains unclear. We aimed to compare the efficacy of 1-day vs 5-day octreotide infusion combined with endoscopic therapy, with the primary outcome of early (5-day) rebleeding under a noninferiority framework and secondary outcomes of 6-week rebleeding and all-cause mortality. METHODS: This nationwide, multicenter, noninferiority, open-label, randomized, controlled trial included 220 patients with cirrhosis and acute esophageal variceal bleeding who underwent endoscopic band ligation in 5 tertiary-care and 3 university-based hospitals across Thailand. They received a 1-day (n = 109) or 5-day (n = 111) regimen of continuous octreotide infusion after successful endoscopy. Rebleeding, transfusion requirements, and mortality were assessed. RESULTS: Most participants were men (180/220), and the average age was 56 years. The 5-day rebleeding (1.83% vs 1.80%, P ≥ 0.99), 6-week rebleeding (8.26% vs 10.81%, P = 0.52), and 6-week all-cause mortality (5.50% vs 6.31%, P = 0.80) rates were similar between the 1-day and 5-day groups. The event-rate difference in early rebleeding was 0.03%, indicating noninferiority (95% CI, 3.50%–3.56%). Patients in the 1-day group required significantly fewer blood transfusions and had a shorter time to oral diet and shorter hospital stay. DISCUSSION: After successful endoscopic band ligation, the 1-day regimen of octreotide had a noninferior effect compared with the standard 5-day regimen in the prevention of 5-day rebleeding and exhibited no significant differences in the prevention of 6-week rebleeding and all-cause mortality. Trial registration number: Thai Clinical Trials Registry, TCTR 20221004008.Keywords
Funding Information
- Gastroenterological Association of Thailand
- Phramongkutklao Hospital and College of Medicine
This publication has 22 references indexed in Scilit:
- Challenges in the Management of Esophagogastric Varices and Variceal Hemorrhage in Cirrhosis – A Narrative ReviewThe American Journal of Medicine, 2023
- Prospects for treatment of esophageal varices considering the safety of endoscopic band ligationHepatology International, 2023
- Baveno VII – Renewing consensus in portal hypertensionJournal of Hepatology, 2022
- Addition of Somatostatin After Successful Endoscopic Variceal Ligation Does not Prevent Early Rebleeding in Comparison to Placebo: A Double Blind Randomized Controlled TrialJournal of Clinical and Experimental Hepatology, 2015
- Short course adjuvant terlipressin in acute variceal bleeding: A randomized double blind dummy controlled trialJournal of Hepatology, 2012
- The Evolving Role of Endoscopic Treatment for Bleeding Esophageal VaricesWorld Journal of Surgery, 2005
- Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertensionGastroenterology, 2001
- Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trialThe Lancet, 1997
- Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligationThe Lancet, 1995
- Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleedingGastroenterology, 1990